Gyroscope Capital Management Group’s Bristol-Myers Squibb BMY Stock Holding History

Gyroscope Capital Management Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-701	Closed	-$3K	–	114
2020 Q1	$3K	Hold	701	–	–	﹤0.01%	110
2019 Q4	$85K	Buy	+701	New	+$40.1K	0.03%	113

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Gyroscope Capital Management Group's BMY Position: Q3 2023 in Review

Gyroscope Capital Management Group increased its Bristol-Myers Squibb (BMY) stake by 13% in Q3 2023, buying an estimated $553K and bringing the position to 80,036 shares worth $4.65M. The position accounts for 1.07% of the portfolio, ranked #29.

Gyroscope Capital Management Group first reported a position in BMY in Q4 2018 and has held it in 20 quarters since. The position peaked at $18.3M in Q4 2019. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Gyroscope Capital Management Group held 80,036 shares of Bristol-Myers Squibb worth $4.65M as of Q3 2023.
Gyroscope Capital Management Group bought 9,024 Bristol-Myers Squibb shares in Q3 2023, an estimated $553K.
Bristol-Myers Squibb made up 1.07% of Gyroscope Capital Management Group's portfolio in Q3 2023, its #29 holding.
Gyroscope Capital Management Group first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 20 quarters since.
Gyroscope Capital Management Group's Bristol-Myers Squibb position peaked at $18.3M in Q4 2019.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Gyroscope Capital Management Group's 13F filing for Q3 2023, filed 13 Nov 2023.